A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
Phase 2
240
about 1.8 years
18–75
25 sites in AZ, CA, FL +11
What this study is about
Researchers are testing whether LY3457263, compared to placebo, can help lower hemoglobin A1c (HbA1c) levels in adults with type 2 diabetes who are already taking semaglutide or tirzepatide. The trial will last about 9 months.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take LY3457263
- 2.Take Placebo
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Change from Baseline in Hemoglobin A1c (HbA1c)
Secondary: Change from Baseline in Fasting Serum Glucose, Percent Change from Baseline in Body Weight
Endocrinology